Study of the BDNF-Val66Met Polymorphism in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal

Centre Hospitalier Esquirol180 enrolled

Overview

This study is complementary to the main study "Brain Derived Neurotrophic Factor Serum Levels Evolution During the Six Months After Alcohol Withdrawal " NCT01491347. The purpose of this study is to evaluate the Bdnf gene - Val66Met polymorphism in subjects with alcohol dependence according to their alcohol consumption status 6 months after withdrawal (relapse or abstinence), in relation to the presence of psychiatric co-morbidities.

Study Type

OBSERVATIONAL

Enrollment

180

Conditions

Alcohol Dependence

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * participation to the study "BDNF serum levels evolution during 6 months after alcohol withdrawal" (main study) * criteria from the main study Exclusion Criteria: * criteria from the main study * released or out from the main study before the follow-up at 4 months after withdrawal

Locations (1)

Centre Hospitalier Esquirol

Limoges, France

Outcomes

Primary Outcomes

Frequency of the Bdnf gene Val/Val, Val/Met and Met/Met phenotypes as a function of relapse

Time frame: at the time of inclusion

Secondary Outcomes

serum BDNF levels variations between inclusion and 6 months later (or 4 months if the participants does not come for the 4 months-follow-up).

Time frame: 6 months after alcohol withdrawal

existence of a psychiatric co-morbidity at the inclusion (major depression, schizophrenia, anxiety disorder)

Time frame: at the time of inclusion

presence of a psychiatric co-morbidity at 6 months after withdrawal (major depression, schizophrenia, anxiety disorder)

Time frame: 6 month after alcohol withdrawal

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.